[Cost effectiveness analysis in health].
作者信息
Pinto-Prades J L, Ortún-Rubio V, Puig-Junoy J
机构信息
Departamento de Economía y Empresa, Centro de Investigación en Economía y Salud, Universidad Pompeu Fabra, Barcelona.
出版信息
Aten Primaria. 2001 Mar 15;27(4):275-8. doi: 10.1016/s0212-6567(01)78808-7.
Abstract
摘要
相似文献
1
[Cost effectiveness analysis in health].[卫生领域的成本效益分析]
Aten Primaria. 2001 Mar 15;27(4):275-8. doi: 10.1016/s0212-6567(01)78808-7.
2
[Improving the transparency and credibility of cost-effectiveness analysis of healthcare interventions].提高医疗保健干预措施成本效益分析的透明度和可信度
Rev Esp Salud Publica. 2016 Mar 23;90:E1.
3
[What is an efficient health technology in Spain?].西班牙的高效卫生技术是什么？
Gac Sanit. 2002 Jul-Aug;16(4):334-43. doi: 10.1016/s0213-9111(02)71933-x.
4
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.西班牙成本效益分析报告方法与结果的质量：一项方法学系统评价
Syst Rev. 2016 Jan 7;5:6. doi: 10.1186/s13643-015-0181-5.
5
[Potential sponsorship bias in cost-effectiveness analyses of healthcare interventions: A cross-sectional analysis].[医疗保健干预措施成本效益分析中的潜在赞助偏差：一项横断面分析]
Aten Primaria. 2017 Jun-Jul;49(6):335-342. doi: 10.1016/j.aprim.2016.08.001. Epub 2017 Jan 3.
6
Health care economic analyses.医疗保健经济分析。
Retina. 2004 Feb;24(1):139-46. doi: 10.1097/00006982-200402000-00019.
7
Theoretically correct cost-effectiveness analysis.理论上正确的成本效益分析。
Med Decis Making. 1999 Oct-Dec;19(4):381-2; discussion 383-4. doi: 10.1177/0272989X9901900404.
8
Quality of life and health economic assessments of age-related macular degeneration.年龄相关性黄斑变性的生活质量与健康经济学评估
Surv Ophthalmol. 2007 Jan;52 Suppl 1:S20-5. doi: 10.1016/j.survophthal.2006.10.014.
9
European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.欧洲肿瘤学学校向欧洲共同体委员会提交的关于“欧洲抗癌计划”癌症护理成本效益的咨询报告。
Eur J Cancer. 1995;31A(9):1410-24. doi: 10.1016/0959-8049(95)00286-r.
10
[Economic aspects. Cost-effectiveness, cost-benefit analysis].[经济方面。成本效益、成本效益分析]
Rev Mal Respir. 1998 Sep;15 Suppl 2:S37-41.
引用本文的文献
1
[Reporting of conflict of interest in cost-effectiveness analyses of healthcare interventions].[医疗保健干预措施成本效益分析中的利益冲突报告]
Aten Primaria. 2017 Feb;49(2):118-120. doi: 10.1016/j.aprim.2016.03.010. Epub 2016 Jul 14.
2
Cost effectiveness of palivizumab in Spain: an analysis using observational data.帕利珠单抗在西班牙的成本效益：基于观察性数据的分析。
Eur J Health Econ. 2010 Feb;11(1):105-15. doi: 10.1007/s10198-009-0206-x. Epub 2009 Dec 5.
3
[Doctors malaise before some uses of cost control: is this an example of ethical immaturity?].[在某些成本控制措施实施之前医生的不适：这是道德不成熟的一个例子吗？]
Aten Primaria. 2003;31(6):389-93. doi: 10.1016/s0212-6567(03)70705-7.
本文引用的文献
1
[Quality of life and allocation of health care resources].[生活质量与医疗保健资源分配]
Gac Sanit. 2000 Mar-Apr;14(2):168-74. doi: 10.1016/s0213-9111(00)71451-8.
2
Intergenerational equity: an exploration of the 'fair innings' argument.代际公平：对“公平 innings”论点的探讨。
Health Econ. 1997 Mar-Apr;6(2):117-32. doi: 10.1002/(sici)1099-1050(199703)6:2<117::aid-hec256>3.0.co;2-b.
3
Rules of evidence and clinical recommendations on the use of antithrombotic agents.抗血栓药物使用的证据规则及临床建议。
Chest. 1992 Oct;102(4 Suppl):305S-311S.
Zotero 插件